Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Posts Double-Digit Q1 Organic Revenue Growth

NEW YORK, May 5 (GenomeWeb News) - Harvard Bioscience yesterday reported a 7.7-percent increase in first-quarter revenues, with organic revenue growth of 11.9 percent.


Revenues for the three months ended March 31, inched up to $17.4 million from $16.1 million in the comparable period of 2005. Excluding the impact of foreign exchange rate changes, however, revenue grew 11.9 percent compared to the same period in 2005, the company said.


The increase in revenues was "across various product lines, and was primarily attributed to an increase in demand for our pre-clinical testing products," Harvard Bio said in a statement.


Net income more than doubled to $540,000 from $202,000 in the first quarter of 2005.


Harvard Bioscience spent $751,000 on R&D in the first quarter, down slightly from $870,000 in the comparable period of 2005.


As of March 31, the company had cash and cash equivalents of $9.8 million, and an additional $2.1 million in discontinued operations.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.